Atossa Therapeutics appoints CFO to support commercial transition [Seeking Alpha]
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: Seeking Alpha
Daniel brings 25+ years of financial leadership in life sciences, including managing $200M+ budgets and SOX compliance. More on Atossa Therapeutics Seeking Alpha's Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Financial information for Atossa Therapeutics Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer ContinuumPR Newswire
- Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for GlioblastomaPR Newswire
- Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation [Yahoo! Finance]Yahoo! Finance
- Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific PresentationPR Newswire
- Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
ATOS
Analyst Actions
- 9/22/25 - Ascendiant Capital
ATOS
Sec Filings
- 12/4/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- ATOS's page on the SEC website